Dec. 16, 2020

Novavax, Inc.
 (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of 

New Zealand
 for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19.

Currently in Phase 3 clinical testing in the 

United Kingdom
 for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M™ to enhance the immune response.

“The global reach of the pandemic requires that all regions of the world have an adequate supply of vaccine available to protect their entire citizenry,” said  Stanley C. Erck , President and Chief Executive Officer of 

. “We appreciate the confidence of the government of 

New Zealand
 and are pleased to contribute to ensuring that New Zealanders will have access to a protein-based vaccine through standard distribution channels, should it receive regulatory approval.”

Read the full article at: